Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

NCT00510276 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

445

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Atomoxetine hydrochloride
DRUG: Placebo

Sponsor

Eli Lilly and Company